Interpace Biosciences (IDXG) Misses Q2 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- S&P 500 and Nasdaq slip as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
August 15, 2022 4:05 PM EDT Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® 2022 Year to Date Net Loss Improves by $1.5... More
